Want to see IN:SUPRIYA full AI Analyst Report?
Top Page
Supriya Lifescience Limited
(SUPRIYA)
Select Model
Select Model
Rating:71Outperform
Price Target:
₹957.00
▲(27.43% Upside)
Action:Upgraded
Date:07/07/26
The score is primarily supported by strong financial quality—especially the very low leverage and solid profitability—partly offset by historical free-cash-flow volatility. Technicals are mixed with a near-term pullback but longer-term moving-average support, while valuation (high P/E and very low yield) is the key drag.
Positive Factors
Strong Revenue Growth
Strong multi-year revenue expansion, including double-digit growth in 2026, indicates renewed demand and improving commercial traction across the API portfolio. Sustained top-line growth can support greater manufacturing utilization, broaden customer reach, and strengthen the company’s ability to fund future expansion.
Negative Factors
History of Revenue Volatility
The 2023 revenue decline shows that growth has not been uninterrupted, creating evidence of sensitivity to demand, product mix, or market conditions. Although the subsequent recovery is encouraging, uneven historical performance means future expansion may not progress consistently across all reporting periods.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
Strong multi-year revenue expansion, including double-digit growth in 2026, indicates renewed demand and improving commercial traction across the API portfolio. Sustained top-line growth can support greater manufacturing utilization, broaden customer reach, and strengthen the company’s ability to fund future expansion.
Read all positive factors
Supriya Lifescience Limited (SUPRIYA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹68.83B
Dividend Yield0.11%
Average Volume (3M)19.56K
Price to Earnings (P/E)34.3
Beta (1Y)1.24
Revenue Growth28.14%
EPS Growth11.38%
CountryIN
Employees521
SectorGeneral
Sector StrengthN/A
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)24.65
Shares Outstanding80,482,800
10 Day Avg. Volume13,315
30 Day Avg. Volume19,559
Financial Highlights & Ratios
PEG Ratio1.92
Price to Book (P/B)3.78
Price to Sales (P/S)5.46
P/FCF Ratio105.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)29.9
Revenue Forecast (FY)₹9.94B
Supriya Lifescience Limited Business Overview & Revenue Model
Company Description
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic,...
How the Company Makes Money
Supriya Lifescience primarily makes money by manufacturing APIs and selling them to pharmaceutical companies and other formulators that use these ingredients to produce finished drugs. Revenue is generated from (1) sale of APIs across its product ...
Supriya Lifescience Limited Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
92
Very Positive
Cash Flow
70
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.75B | 8.28B | 6.96B | 5.70B | 4.51B | 5.19B |
| Gross Profit | 5.63B | 4.49B | 3.84B | 2.80B | 2.80B | 2.89B |
| EBITDA | 2.99B | 3.05B | 2.71B | 1.84B | 1.37B | 2.22B |
| Net Income | 1.98B | 2.09B | 1.88B | 1.19B | 898.57M | 1.52B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 13.57B | 11.12B | 9.21B | 8.20B | 7.35B |
| Cash, Cash Equivalents and Short-Term Investments | 788.67M | 788.67M | 791.54M | 749.56M | 1.58B | 2.25B |
| Total Debt | 0.00 | 54.35M | 53.80M | 54.88M | 224.68M | 274.15M |
| Total Liabilities | -11.98B | 1.59B | 1.16B | 1.06B | 1.21B | 1.19B |
| Stockholders Equity | 11.98B | 11.98B | 9.97B | 8.15B | 6.99B | 6.16B |
Cash Flow | ||||||
| Free Cash Flow | 133.16M | 429.88M | 101.89M | -323.48M | -422.13M | -111.03M |
| Operating Cash Flow | 555.65M | 1.95B | 1.73B | 1.13B | 661.87M | 488.01M |
| Investing Cash Flow | -304.29M | -1.88B | -1.62B | -1.74B | -1.33B | -598.22M |
| Financing Cash Flow | -10.75M | -79.93M | -65.47M | -223.59M | -97.77M | 1.50B |
Supriya Lifescience Limited Technical Analysis
Positive
751.00
Price Trends
853.46
Positive
827.55
Positive
757.66
Positive
Market Momentum
0.77
Negative
66.03
Neutral
88.64
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SUPRIYA, the sentiment is Positive. The current price of 751 is below the 20-day moving average (MA) of 813.19, below the 50-day MA of 853.46, and below the 200-day MA of 757.66, indicating a bullish trend. The MACD of 0.77 indicates Negative momentum. The RSI at 66.03 is Neutral, neither overbought nor oversold. The STOCH value of 88.64 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SUPRIYA.
Supriya Lifescience Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹107.73B | 42.15 | ― | 0.21% | -27.51% | -34.49% | |
71 Outperform | ₹68.83B | 34.32 | ― | 0.11% | 28.14% | 11.38% | |
62 Neutral | ₹23.35B | -327.67 | ― | 0.56% | 10.26% | -162.28% | |
56 Neutral | ₹27.34B | 40.05 | ― | 0.11% | -20.86% | -34.51% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
44 Neutral | ₹34.35B | -36.00 | ― | 0.09% | 78.89% | -50.29% | |
43 Neutral | ₹175.87B | -361.91 | ― | ― | 27.15% | 40.46% |
* General Sector Average
IN:SUPRIYA
Supriya Lifescience Limited
915.65
261.68
40.01%
IN:BLUEJET
Blue Jet Healthcare Limited
580.95
-149.07
-20.42%
IN:DCAL
Dishman Carbogen Amcis Ltd.
173.85
-106.85
-38.07%
IN:PANACEABIO
Panacea Biotec Limited
393.40
-26.00
-6.20%
IN:ZOTA
Zota Health Care Ltd.
1,113.10
-380.96
-25.50%
IN:ONESOURCE
OneSource Specialty Pharma Limited
1,586.10
-253.20
-13.77%
Supriya Lifescience Limited Corporate Events
Supriya Lifescience Seeks Shareholder Nod to Reappoint Whole Time Director via E-Voting
Jul 21, 2026
Supriya Lifescience Limited has initiated a postal ballot process to seek shareholder approval for the special resolution to re-appoint Mr. Balasaheb Sawant as Whole Time Director and Key Managerial Personnel for a three-year term from May 26, 202...
Supriya Lifescience Confirms SEBI Compliance on Dematerialised Securities
Jul 9, 2026
Supriya Lifescience Limited has reported that its registrar and share transfer agent, MUFG Intime India Private Limited, has issued a certificate confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, ...
Supriya Lifescience Reports Customs Probe Into Senior Sales Executive
Jul 4, 2026
Supriya Lifescience has disclosed that its General Manager for Sales and Marketing, Sreekant Sreedharan, is under investigation by the Special Investigation and Intelligence branch of the Customs Department and has been placed in judicial custody ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.